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ORIGINAL ARTICLE
Gestational weight gain by reduced brain
melanocortin activity affects offspring energy balance
in rats
ACM Heinsbroek and G van Dijk
Unit Neuroendocrinology, Center for Behaviour and Neurosciences, University of Groningen, NN Haren, The Netherlands
Introduction: Excessive gestational body weight gain of mothers may predispose offspring towards obesity and metabolic
derangements. It is difficult to discern the effects of maternal obesogenic factorsFsuch as diet and/or thrifty genetic
predispositionFfrom gestational weight gain per se.
Methods: For this reason, genetically normal Wistar rats that were fed regular chow were rendered hypothalamically obese by
chronic third-cerebral ventricular (i3vt) infusion during pregnancy and lactation with the melanocortin-3,4 receptor blocker
SHU9119. This procedure caused significant increases in body weight gain during pregnancy and lactation compared with
controls, and the effects thereof on offspring energy balance and fuel homeostasis were investigated.
Results: At birth, litter weight and size, but not individual pup weight, of SHU9119-treated mothers were significantly smaller
than controls. In litters culled to eight, pup weight gain during lactation was only transiently increased by treatment. After
weaning, however, male offspring of SHU9119-treated mothers became increasingly heavier over time relative to controls until
killing at 9 months. This effect was only transient in females. Increased body weights of males were not associated with
disturbances in glucose homeostasis, but with increased energy expenditure instead. Multiple regression analysis revealed that
gestational body weight gain, irrespective of the group, contributed positively to increased visceral fat deposition and
carbohydrate oxidation in the male offspring. In contrast, the pre-pregnancy body weight of mothers contributed positively to
male offspring daily energy expenditure, subcutaneous fat and eviscerated carcass as well as structural organ weights. In female
offspring, gestational body weight gain, but not pre-gestational body weight, contributed both to aspects of weight gain as well
as to the shift of fat oxidation toward carbohydrate oxidation.
Conclusion: Gestational weight gain induced by low brain melanocortin receptor activity can lead to increased body weight
gain in the offspring (particularly in males) independent of obesogenic dietary and/or thrifty genetic predisposition.
International Journal of Obesity (2009) 33, 104–114; doi:10.1038/ijo.2008.211; published online 11 November 2008
Keywords: pregnancy; lactation; SHU9119; maternal obesity; generational effects; metabolic imprinting
Introduction
According to the report of a joint WHO/FAO expert
consultation in 2003, over 1 billion people are estimated to
be overweight,1 and conditions associated with obesityFfor
example, type II diabetes mellitus, cardiovascular diseases
and certain types of cancerFhave devastating health
consequences. If no actions are taken, the economic
consequences to societies will be staggering in the near
future.2,3 The contributing factors are probably a sedentary
lifestyle and changes in dietary habits,4 particularly in
genetically predisposed obese individuals.5 Obesity-prone
individuals may differ from obesity-resistant ones because of
the reduced efficacy with which the adipocyte hormone
leptin interacts with neuronal networks involved in the
control of ingestive behaviour, neuroendocrine outflow and
metabolism.6–8 A key network involved in the signalling of
leptin is the brain melanocortin (MC) system.9 Under ad
libitum feeding, non-obese conditions, leptin stimulates
arcuate nucleus (ARC) neurons that synthesize and secrete
a-melanocyte stimulating hormone, and reduces the
activity of ARC neurons that synthesize and secrete agouti-
related peptide (AgRP).10,11 The latter neurons contain the
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orexigenic neuropeptide Y (NPY) whose synthesis and secre-
tion are also depressed by leptin .12 a-MSH acts agonistically
and AgRP inverse agonistically on brain MC receptors, which
together underlie reduced ingestive behaviour and increased
metabolic rate.13 The idea that MC receptors are downstream
from leptin signalling comes from studies in which the third-
intracerebroventricular (i3vt) effects of leptin could be
blocked by the cyclic a-MSH analogue SHU9119,14 which is
a strong antagonist of MC3/4 receptors.15 Continued i3vt
treatment with SHU9119 has been shown to cause obesity in
rats.9,16 Leptin resistance caused by polymorphisms in MC-
associated genes constitutes the most prevalent monogenic
causes of obesity known today.17,18
Obesity is not caused only by interaction between genes
and the traditional adult risk factors. It is becoming
increasingly clear that the interplay between genes and the
embryonic, fetal and early postnatal environment is also of
tremendous importance. Although initial observations on
humans focused on the relationship between low birth
weight and risk of adult obesity and metabolic syndrome,19
mothers who are overweight during pregnancy have
children with high risk of increased birth weight and/or
adiposity.20 In turn, this can increase the risk for childhood
and adult obesity.21 It is difficult, however, to discern the
direct effects of gestational obesity from dietary or genetic
factors that drive the obese state in the offspring. To study
the effects of gestational weight gain on offspring body
weight and on the factors related to fuel homeostasis
independent of genetic predisposition or diet, we first aimed
at introducing increased weight gain in rats during gestation
and lactation by i3vt SHU9119 infusion in a dose earlier
found to be effective in male rats.9,16 It was already known
from the work of Polidori and Geary22 that female rats are
equally sensitive to the orexigenic actions of central
SHU9119 treatment, as compared with male rats, and that
oestrogen does not affect the sensitivity to SHU9119, but no
studies have been performed to assess the effects of SHU9119
treatment on body weight gain during pregnancy and
lactation. If reduced brain MC activity during pregnancy
and lactation causes increased weight gain in these animals
as well as in their offspring, the implication could be that
polymorphisms in genes that inhibit the activity of the brain
MC system may –besides being passed on geneticallyFalso
provide a perinatal environment leading to increased weight
gain and disturbances in fuel homeostasis in the offspring
through a non-genetic route.
Methods
Housing
All the rats used in these experiments were from the Wistar
strain and obtained from Harlan Netherlands (Horst). They
were initially group-housed in our animal rooms at room
temperature (20±2 1C) on a 12:12 light–dark cycle (lights off
at 1400 h), with food (RMHB-laboratory chow, Charles River)
and water available ad libitum. All methods were approved by
the Local Ethics Committee of the University of Groningen.
Pregnancy and lactation
After a habituation period of several days in our animal
quarters, 20 female rats (270–290 g, between 4–5 months of
age) were anesthetized under isoflurane/N2O inhalation and
implanted stereotaxically with a 22 G stainless steel guide
cannula (Plastics One, Roanoke, VA, USA) aimed i3vt.23 After
surgery, each rat was given 1.0 mg kg1 flunixin–meglumin
s.c. (Schering-Plough, Maarssen, The Netherlands) for an-
algesia, and housed individually in a plastic cage (lXbXh:
252535 cm) with clean wood shavings and shredded
cardboard. After recovery from surgery, correct cannula
placement was confirmed by induction of a drinking
response following i3vt injection of 10 ng of angiotensin-
II.23 Twenty male rats in separate cages were housed in the
same room to stimulate oestrus cycling in the female rats,
which was assessed by taking daily vaginal smears just before
the start of the dark period. On confirmation of cyclicity for
at least four cycles, each female was housed together with a
male for one day during the end of the pro-oestrus or the
beginning of oestrus. Copulation was confirmed by the
presence of vaginal plugs and/or the presence of sperm cells
in the vaginal smears (day 1 of pregnancy). Maternal body
weights were assessed until day 25 post-delivery. Because
pups started to ingest food and drink water after day 16 of
lactation, no food and water intake recordings are shown
beyond that day.
At day 4 of presumed pregnancies, animals were divided
into two groups that had approximately the same mean
body weight (290.2±5.3 vs 296.5±5.5 g, P¼0.403). Under
isoflurane inhalation anaesthesia (N2O was excluded because
of its reported risk in inducing abortion24,25), each rat had an
osmotic minipump (Alzet 2004, pumping rate 0.25 ml h1
over 28 days; Alza, Palo Alto, CA, USA) implanted sub-
cutaneously. These minipumps were connected with poly-
ethylene tubing (PE50) to an injector placed permanently
into the previously positioned i3vt cannula. In one group
(n¼8), pump and connector tubings were filled to deliver
sterile saline. In the other group (n¼12), pumps and
connector tubings were filled to deliver SHU9119 ((Ac-Nle4,
Asp5, D-2-Nal7, Lys10)-cyclo-a-MSH4–10 amide, M-4603;
Sigma-Aldrich Chemie, Sternheim, Germany, 0.5 nmol in
sterile saline per day). This dose of SHU9119 causes
hyperphagia and obesity in adult male Wistar rats.9 Eight
out of 12 SHU9119-treated rats (67%) and five out of eight
saline-treated rats (63%) became pregnant. Two SHU9119-
treated mothers were excluded as they developed inflamma-
tion around the minipump during a late stage of pregnancy
and started to lose weight gradually during lactation.
Non-pregnant SHU9119-treated (n¼4) and saline-treated
rats (n¼3) served as non-pregnant controls. One additional
non-operated and non-pregnant control group (n¼3) was
added to the study to assess the effects of saline treatment
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per se. As the body weight and ingestion parameters
were identical among saline-treated and non-treated
controls, we decided to group them as ‘non-pregnant’
controls (n¼6).
On the day of birth, litters of healthy mothers were
weighed, counted and equalized to eight. In the saline-
treated group, litter counts ranged between 7 and 14. The
litter of seven pups was substituted by a surplus pup from a
large litter. In the SHU9119-treated group, litter counts
ranged from 7 to 10. One whole litter was divided among
others, as the number of surplus pups was insufficient. The
‘cross-fostered’ pups in the saline and SHU9119 groups
were toe-clipped and not used for further analysis. At day 17
of lactation, one litter from a saline-treated and from an
SHU9119-treated mother was terminated to assess the
biochemical and anatomical characteristics, leaving four
litters per group for offspring analysis after weaning. Except
for individual pup weight registration at day 16, the
remaining litters were left undisturbed until weaning. At
day 25, mothers were killed by carbon dioxide exposure after
which body composition analysis was performed. Intestines,
liver, spleen, adrenals, kidneys, thymus, retroperitoneal fat,
subcutaneous fat (including skin) and muscle (stripped
carcass without subcutaneous fat and skin) were all removed
and weighed separately.
Offspring
Metabolic and endocrine parameters. After weaning, offspring
rats were housed in numbers of two 2–3 in type IV cages with
males and females separated, mixed among litters, and
weighed at 1, 2, 3, 6 and 9 months of age. Basal fuel and
hormone levels were assessed at 2 months of age by tail
bleeding (0900–1000 h). Samples (500 ml) were collected
within 1 min into chilled tubes (0 1C) containing 0.05 g ml1
EDTA. All blood samples mentioned here and elsewhere were
centrifuged for 15 min. at 1500 g, 4 1C. Plasma samples were
stored at 20 1C until analysis for insulin, leptin, adiponec-
tin and glucose content. Glucose levels were measured by the
ferricyanide method of Hoffman26 (Technicon Auto Analyzer
TMII). Plasma levels of insulin (Linco kit no. RI-13K), leptin
(Linco kit no. RL-83K) and adiponectin (Linco kit no. MADP-
60HK) were determined by commercial assays. After blood
sampling at 2 months, offspring rats were put individually in
cages for 10 days to measure food and water intake. Between
days 2 and 9 of this individual housing period, animals were
placed individually during a 26 h period in a respirometric
chamber (lbh: 253525 cm), with food and water
available ad libitum. After habituation for 2 h, oxygen
consumption (VO2 , l h
1) and carbon dioxide production
(VCO2 , l h
1) were recorded, and carbohydrate oxidation
(CHO-ox, mg min1), fat oxidation (FAT-ox, mg min1)
27and metabolic rate (MR, kJ h1)28 were calculated. Resting
metabolic rate (RMR, kJ h1) was defined as the lowest
(running) mean metabolic rate (MR) recorded over half
an hour anywhere during the 24-h measurement. MR
over 24 h was used to calculate the daily energy expenditure
(DEE, kJ d1).
Glucose homeostasis. To investigate the effects of maternal
SHU9119 treatment versus saline treatment during preg-
nancy and lactation on offspring glucose homeostasis, an
oral glucose tolerance test (OGTT) at 3 months as well as an
intravenous glucose tolerance test (IVGTT) at 7 months was
performed.
OGTT: Animals were trained over 1 week to swallow a
gavage tube (outer diameter: 1.5 mm) that could be
advanced in the esophagus for gastric injections. During
the night before the experiment, animals were individually
housed and received 6 g of food (semi-fasted), with water
available ad libitum. On the next morning, a basal blood
sample (150 ml) was taken by tail bleeding within 1 min, and
the animals received 1 g of glucose in 5 ml water by gavage
and were put back into their cage. Further blood samples
were taken by tail bleeding at 15, 30 and 45 min. In all
samples, the levels of glucose and insulin were assessed in
plasma by the abovementioned methodology.
IVGTT: At 6.5 months of age, animals were housed
individually (lbh: 252535 cm) and surgically
equipped under isoflurane/N2O inhalation anaesthesia with
silicon cannulas in the right and left jugular veins according
to methods described earlier.29 The cannulas were filled with
55% polyvinylpyrrolidone in heparinized water (400 U ml1)
to maintain patency between surgery and experimental
blood sampling. Animals were injected with 1.0 mg kg1
flunixin–meglumin (s.c.) (Schering-Plough, Maarssen, The
Netherlands) for analgesia after surgery. After recovery from
surgery, animals were habituated three times to blood
sampling during the middle of the light phase. Two hours
before the actual IVGTT, animals were food-deprived and
connected to tubing for remote and stress-free blood
sampling and infusion. Two basal blood samples (150 ml)
were taken after which (t¼0) a glucose infusion was started
(10 mg min1 in 2 ml saline over 20 min). Blood samples for
determination of plasma glucose and insulin levels were
taken at t¼1, 3, 5, 7, 10, 15, 20, 23, 26, 30, 40 and 50 min.
Two weeks later, females from one litter were taken out of
the experiment because of inflammation around the jugular
vein cannulas.
Carcass analysis. At 9 months, all animals from the
remaining litters were decapitated after short CO2 exposure
for body composition analysis. Blood was collected for end
point fuel and hormone analysis as described above. The
following organs were removed and weighed immediately:
intestines, liver, spleen, adrenals, kidneys, thymus, retro-
peritoneal fat, epidydimal fat, subcutaneous fat (including
skin) and muscle (stripped carcass without skin).
Statistical analysis
Maternal body weight, food and water intake were analyzed
using repeated measures ANOVA with treatment as between
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subject factor. The effects of SHU9119 versus saline treat-
ment on carcass parameters of mothers and litter character-
istics were analyzed using t-tests. The effects of SHU9119
treatment during pregnancy relative to control treatment on
offspring growth curves (after natural log transformation)
were analyzed with General Linear Models using a repeated
measures design in which litters were nested in treatments
and litter was designated as a random factor. Individual
blood glucose and plasma insulin responses during the
OGTT and IVGTT experiments were calculated by area under
the curve (AUC). Basal fuel and hormone levels, metabolic
parameters, ingestive parameters, glucose homeostasis
(based on AUCs) and body composition were analyzed with
General Linear Models with nested design as mentioned
above, and the litter designated as a random factor. All
results from male and female offspring were analyzed
separately. Multiple regression analysis was performed to
investigate how variation in peri-gestational weight para-
meters of mothers and their treatment contributed to
variation in various parameters related to body weight and
fuel homeostasis in the offspring. In this event, scores from
animals per gender were averaged within each litter. In all
tests, Po0.05 was considered significant. Data are presented
as averages ±s.e.m. All statistical analyses were performed
using SPSS 15.0 for Windows.
Results
Effects of SHU9119 and saline treatment on pregnancy and
lactation
ANOVA detected significant differences in food intake over
time during pregnancy (F(17,153)¼8.98; Po0.0001) and
lactation (F(16,128)¼38.70; Po0.0001) (Figure 1a) compared
with non-pregnant controls. Food intake responses were
stronger over time in SHU9119-treated (though not signi-
ficantly different from SHU9119-treated non-pregnant rats)
than in saline-treated females during pregnancy (time treat-
ment: F(17,153)¼2.74; P¼0.001). During lactation, however,
differences in food intake between SHU9119-treated
and control-treated rats were lost (time treatment:
F(16,128)¼1.36; P¼0.17). In addition, water intake increased
significantly over time during pregnancy (F(17,153)¼8.49;
Po0.0001) and lactation (F(16,128)¼23.24; Po0.0001)
(Figure 1b), and increases during pregnancy were again more
pronounced in SHU9119-treated than in saline-treated females
(time treatment: F(17,153)¼2.53; P¼0.001). No interaction
was found during lactation (time treatment: F(16,128)¼1.05;
P¼0.40). Body weight increased significantly over time during
pregnancy (F(20,180)¼95.46; Po0.001) and lactation
(F(25,200)¼3.99; Po0.001) (Figure 1c). During pregnancy,
body weight increase was more pronounced in SHU9119-
treated than in saline-treated females (time treatment:
F(20,180)¼5.36; Po0.0001). During lactation, no interaction
effect was found F((25,200)¼1.53; P¼0.057). Relative to the
pre-gestational body weight, body weight gain of SHU9119-
treated females was 177±27 g (þ59% increase), which was
significantly larger (F(1,9)¼5.689, P¼0.041) than that of
saline-treated females (increase of 109±10g, þ38%). At
parturition, maternal drop in body weight was different
between SHU9119-treated (58±6 g, 12%) and saline-treated
(88.6±10g, 22%) females (F(1,9)¼8.77; P¼0.016). During
lactation SHU9119-treated females were still heavier than
saline-treated females (F(1,8)¼8.96; P¼0.017). Non-pregnant
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Figure 1 Food intake (a), water intake (b), and body weight (c) of female
rats during pregnancy and lactation and their respective controls are depicted.
Treatments include i3vt infusion in pregnant/lactating rats of the melanocortin
blocker SHU9119 (SHU pregnant, n¼6, but n¼ 5 from day 1 of lactation) and
saline (Sal pregnant, n¼5), and i3vt infusion in non-pregnant/non-lactating
rats of SHU9119 (SHU non-pregnant, n¼ 4) and saline or no infusion (Sal/con
non-pregnant, n¼6). Data are expressed as mean±s.e.m.
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normal 20 g day1 until the end of the infusion period (at
approximately day 10 of lactation in the lactating animals)
compared with non-pregnant controls, resulting in continued
increased body weight.
Litter and mother characteristics
Table 1 shows characteristics of litters from SHU9119-treated
and saline-treated mothers on the day of birth. Litters from
SHU9119-treated mothers were significantly lighter than
those from saline-treated mothers (P¼0.006), which was
partly explained by the smaller litter size (P¼0.043). There
was no difference in individual pup weight at birth
(P¼ 0.727). Dead/alive ratios (P¼0.204) and male/female
ratios (P¼0.551) were similar in SHU9119- and saline litters.
At 16 days of age, pups in litters of SHU9119-treated mothers
were significantly heavier (P¼0.022), but this difference
disappeared at weaning at 25 days of age (P¼0.790). At day
25 of lactation, mothers were killed by decapitation for
examination of body composition (Table 2), and the body
weight of SHU9119-treated mothers was higher than that of
saline-treated mothers (P¼0.005). Adiposity was increased
in SHU9119-treated mothers, as indicated by their signifi-
cantly heavier retroperitoneal (P¼0.001) and subcutaneous
fat (P¼0.002) pads. In addition, liver (P¼0.005), gastro-
intestinal tract (P¼0.013), kidneys (P¼0.016) and thymus
(P¼ 0.002) were heavier in SHU9119-treated mothers. No
differences between treatment groups were observed in the
spleen, adrenals and muscle weight.
Effect of maternal SHU9119 and saline treatment on offspring
body weight
Offspring body weights from saline-treated and SHU9119-
treated mothers from weaning until 9 months of age are
shown in Table 3. General Linear Models with time and
treatment (in which litters were nested) as factors revealed a
significant interaction effect in male offspring (B¼13.50,
s.e.¼5.73, w2¼5.55, P¼0.018), and only a treatment effect
in females (B¼18.89, s.e.¼9.11, w2¼4.30, P¼0.038). Body
weights of male offspring from SHU9119-treated mothers
were higher than those from saline-treated mothers from the
third month until decapitation at 9 months of age. Body
weight of female offspring from SHU9119-treated mothers
were only transiently increased relative to female offspring
from saline-treated mothers, that is, from the second until
the sixth month of age.
Effect of maternal SHU9119 and saline treatment on offspring
metabolic and ingestive parameters
Using General Linear Models with treatment (in which litters
were nested) as factor revealed that neither the assessed
plasma hormone and fuel levels nor the ingestive parameters
were different between offspring groups (Table 4). However,
RMR (F(1,21)¼54.238, P¼0.041) and DEE ((F1,21)¼5.443,
P¼0.046) in male offspring from SHU9119-treated mothers
were 12.5 and 7.6%, respectively, higher than in male
offspring from saline-treated mothers. CHO oxidation
tended to be increased in male offspring from SHU9119-
treated mothers relative to controls (F(1,21)¼4.306,
P¼0.066). Only trends were observed in females (Table 5).
The differences in weight observed above were not associated
with deteriorations in glucose homeostasis, as indicated by
the similar outcomes of the OGTT and IVGTT.
Multiple regression analysis
Although maternal treatment effects on offspring body
composition and glucose homeostasis failed to reach
statistical significance, there were in almost all assessed
parameters strong effects of litter in the nested design
Table 1 Litter characteristics of SHU9119- and saline-treated mothers
Litters from Saline-treated mothers SHU9119-treated mothers
Litter size 11.0 (1.4) 7.3 (1.1)*
Litter weight (g) 76.3 (3.9) 49.18 (6.92)**
Dead/alive ratio 0 0.089 (0.064)
Male/female ratio 1.27 (0.39) 0.91 (0.48)
Pups still alive at day 1 11.0 (1.4) 6.7 (1.1)*
Pup birth weight (g) 6.46 (0.26) 6.55 (0.11)
Pup weight 16 days (g) 37.9 (1.7) 47.2 (3.2)*
Pup weight 25 days (g) 95.5 (6.4) 98.3 (5.8)
Pups were counted and weighed individually upon finding the litter at day 0 of
lactation. Characteristics of litters at birth of healthy mothers only were
analyzed (saline: n¼ 5, SHU9119: n¼ 6). After counting the surviving pups at
day 1, litters were equalized to eight. One litter from a SHU9119-treated
mother was divided over the other litters from SHU9119-treated mothers,
because surplus pups were insufficient to equalize all litters to eight pups.
Therefore, results at day 16 are based on five saline and five SHU9119 litters.
One litter of each group was terminated on day 17 of lactation to assess
biochemical and anatomical characteristics, leaving four litters from saline-
treated mothers and four litters from SHU9119-treated mothers at day 25.
Asterisks denote significant difference (*Po0.05; **Po0.01).
Table 2 Whole body and organ weights presented as averages (±s.e.m.)





Body weight (g) 289.4 (10.7) 406.3 (29.3)**
Liver (g) 12.1 (1.1) 19.2 (2.1)*
Gastrointestinal tract
(full) (g)
28.3 (4.2) 50.8 (6.0)*
Spleen (g) 0.69 (0.04) 0.82 (0.10)
Kidneys (g) 2.33 (0.07) 3.06 (0.24)*
Thymus (g) 0.196 (0.019) 0.481 (0.060)**
Adrenals (g) 0.084 (0.010) 0.114 (0.012)
Subcutaneous fat (g) 44.8 (2.4) 83.9 (8.3)**
Retroperitoneal fat (g) 5.9 (1.1) 30.3 (4.6)**
Carcass (g) 164.9 (5.2) 178.9 (5.0)
Body composition was assessed in healthy mothers that successfully reared
their pups to weaning. Asterisks denote significant difference (*Po0.05;
**Po0.01).
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Table 3 Treatment effects of i3vt SHU9119 versus saline during pregnancy and lactation on offspring body weight presented as averages (±s.e.m.)
Offspring (based on individual scores) from Saline-treated mothers SHU9119-treated mothers PGBW GBWG LW and/or GP
Males
1 month (g) 104.7 (2.4) 100.0 (3.0) F F F
2 months (g) 301.4 (4.1) 319.1 (6.5)* F F F
3 months (g) 417.4 (5.2) 463.0 (10.5)*** m, P¼0.049 F F
6 months (g) 521.2 (6.2) 555.9 (12.3)** F F F
9 months (g) 560.8 (9.8) 600.7 (12.5)* m, P¼0.018 F F
Females F
1 month (g) 94.7 (2.8) 95.9 (2.7) F F F
2 months (g) 208.0 (4.3) 223.3 (3.2)** F F GP, P¼0.01
3 months (g) 260.3 (6.1) 281.7 (4.0)** F F GP, P¼0.04
6 months (g) 293.1 (7.8) 319.3 (6.7)* F F F
9 months (g) 325.1 (6.8) 344.4 (7.4) F m, P¼0.001 GP, P¼ 0.001
Asterisks denote significant difference (*Po0.05; **Po0.01, ***Po0.001), and multiple regression analysis with pre-gestational body weight (PGBW), gestational
body weight gain (GBWG), and litter weight (LW) and/or group (GP) as factors. m,k indicates direction of interaction.
Table 4 Treatment effects of i3vt SHU9119 versus saline during pregnancy and lactation on male offspring characteristics are presented as averages (±s.e.m.)
Male offspring Saline-treated mothers SHU9119-treated mothers PGBW GBWG LW and/or GP
Fuel and hormones 2 months
Glucose (mM) 6.33 (0.09) 7.08 (0.20) F m, P¼0.005 F
Insulin (ng ml1) 2.56 (0.16) 3.04 (0.43) F m, P¼0.011 F
Leptin (ng ml1) 4.34 (0.26) 5.16 (0.69) F F F
Adiponectin (ng ml1) 3378 (138) 4064 (201) F F F
Fuel and hormones 9 months
Glucose (mM) 6.28 (0,12) 6.36 (0.18) F m, P¼0.006 GP, P¼0.004 LW, P¼ 0.001
Insulin (ng ml1) 3.47 (0,34) 2.93 (0.44) F F F
Leptin (ng ml1) 5.86 (0.70) 6.08 (0.36) F F F
Adiponectin (ng ml1) 2052 (139) 2421(146) F F F
Food and water intake
Food intake (g day1) 22.58 (0.81) 23.01 (0.57) F F F
Water intake (g day1) 29.45 (1.98) 33.8 (1.4) F F F
Substrate metabolism
CHOox (mg min1) 1051 (37) 1183 (25) F m, P¼0.018 F
FATox (mg min1) 1338 (150) 1171 (79) F F F
RMR (kJ h1) 8.19 (0.24) 9.20 (0.24)* F F F
DEE (kJ day1) 264.8 (3.4) 284.8 (5.6)* m, P¼0.015 F F
OGTT
AUC (0–45) glucose 290.3 (4.1) 314.6 (10.3) m, Po0.0001 F F
AUC (0–45) insulin 231.6 (8.2) 251.9 (23.5) m, P¼0.045 F F
IVGTT
AUC (0–50) glucose 320.2 (7.3) 320.5 (7.5) F F F
AUC (0–50) insulin 168.6 (13.0) 151.4 (12.4) F F F
Body composition
Liver (g) 20.4 (0.4) 21.1 (0.6) m, P¼0.034 F F
Intestines (g) 33.3 (0.7) 33.0 (0.6) F F F
Spleen (g) 1.02 (0.05) 1.13 (0.07) F F F
Kidneys (g) 3.33 (0.13) 3.88 (0.16) F F F
Thymus (g) 0.37 (0.02) 0.48 (0.05) F m, P¼0.039 F
Adrenals (g) 0.084 (0.003) 0.078 (0.004) F F F
Subcutaneous fat (g) 102.7 (3.4) 112.4 (4.6) m, P¼0.028 F F
Retroperitoneal fat (g) 7.33 (0.60) 10.0 (1.4) F m, P¼0.013 GP, P¼ 0.077
Epidydimal fat (g) 16.9 (0.7) 19.3 (1.0) F m, P¼0.039 F
Carcass (g) 328.4 (6.1) 350.7 (6.7) m, P¼ 0.04 F F
Results are based on nested design analysis (*Po0.05), and multiple regression analysis with pre-gestational body weight (PGBW), gestational body weight gain
(GBWG), and litter weight (LW) and/or group (GP) as factors. m,k indicates direction of interaction.
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analysis. This means that individual mother–litter interac-
tions were relatively large compared with the effects of
SHU9119 versus saline treatment on offspring characteris-
tics. Therefore, we performed multiple regression analysis
in which (1) body weight of dams at day 0 of pregnancy
(pre-gestational body weight), (2) body weight gain during
pregnancy (gestational body weight gain) and (3) treatment
group were included as independent factors. Using backward
multiple regression analysis, these factors were analyzed on
their relative significance in explaining variation in various
offspring characteristics averaged per litter (dependent
factors). Only when a significant interaction was found of
gestational body weight gain and a relevant parameter in the
offspring did we include litter weight as a factor. This
procedure was chosen as litter weight is by definition a major
component of body weight gain during pregnancy, but it
may not necessarily be related to pre-gestational body
weight. Indeed, pre-gestational body weight was signifi-
cantly correlated neither with gestational body weight gain
nor with litter weight.
In male offspring (Table 4), gestational body weight gain of
mothers contributed in a positive direction to plasma
glucose (F(1,7)¼18.93) and plasma insulin (F(1,7)¼12.80)
at 2 months of age, plasma glucose at 9 months of age
(F(2,7)¼16.8, treatment group contributed as well), CHO
oxidation (F(1,7)¼10.33), and to the end point weights
of the thymus (F(1,7)¼6.953), retroperitoneal fat
(F(2,7)¼8.03; near-significant treatment effect as well), and
epidydimal fat (F(1,7)¼6.95). Only plasma glucose at 9
months was affected more strongly by litter weight
(F(2,7)¼39.21) than by gestational weight gain per se. The
pre-gestational body weight of mothers contributed in a
positive direction to body weight at 3 months (F(1,7)¼6.05)
and 9 months (F(1,7)¼10.45) of age (Table 3), to DEE
Table 5 Treatment effects of i3vt SHU9119 versus saline during pregnancy and lactation on female offspring characteristics are presented as averages (±s.e.m.)
Female offspring Saline-treated mothers SHU9119-treated mothers PGBW GBWG LW and/or GP
Fuel and hormones 2 months
Glucose (mM) 5.85 (0.11) 3.09 (0.06) F F F
Insulin (ng ml1) 1.64 (0.10) 2.20 (0.14) F F F
Leptin (ng ml1) 2.52 (0.12) 2.81 (0.24) m, P¼0.026 F F
Adiponectin (ng ml1) 4013 (324) 3964 (118) F F F
Fuel and hormones 9 months
Glucose (mM) 5.66 (0,21) 5.85 (0.17) m, P¼0.002 F F
Insulin (ng ml1) 2.30 (0.40) 3.14 (0.48) F F F
Leptin (ng ml1) 3.53 (0.63) 3.04 (0.39) F F F
Adiponectin (ng ml1) 2619 (373) 3151(233) F F F
Food and water intake
Food intake (g day1) 16.0 (0.9) 16.7 (0.8) F F F
Water intake (g day1) 23.8 (1.6) 25.9 (1.6) F F F
Substrate metabolism
CHOox (mg min1) 795 (34) 835 (25) F m, P¼ 0.007 F
FATox (mg min1) 945 (112) 831 (105) F k, P¼ 0.004 F
RMR (kJ h1) 6.10 (0.14) 6.06 (0.15) F F F
DEE (kJ day1) 198.6 (3.4) 200.7 (3.9) F m, P¼ 0.052 F
OGTT
AUC (0–45) glucose 302.2 (12.5) 305.7 (6.7) F F F
AUC (0–45) insulin 238.7 (22.3) 293.2 (22.9) F F F
IVGTT
AUC (0–50) glucose 338.3 (7.8) 338.0 (14.0) F F F
AUC (0–50) insulin 181.5 (19.0) 134.6 (14.0) F F F
Body composition
Liver (g) 10.4 (0.5) 12.0 (0.5) F F F
Intestines (g) 22.0 (1.2) 26.0 (1.5) F F F
Spleen (g) 0.74 (0.05) 0.90 (0.05) F F F
Kidneys (g) 2.41 (0.10) 2.77 (0.15) F F F
Thymus (g) 0.36 (0.08) 0.45 (0.05) F F F
Adrenals (g) 0.089 (0.003) 0.112 (0.008) F F F
Subcutaneous fat (g) 51.7 (2.6) 54.7 (2.0) F m, P¼ 0.009 F
Retroperitoneal fat (g) 13.0 (1.7) 15.8 (1.4) F F
Carcass (g) 191.5 (3.6) 196.8 (5.3) F m, P¼ 0.018 F
Results are based on nested design analysis, and multiple regression analysis with pre-gestational body weight (PGBW), gestational body weight gain (GBWG), and
litter weight (LW) and/or group (GP) as factors. m,k indicates direction of interaction.
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(F(1,7)¼11.23), to the AUC of glucose (F(1,7)¼60.15)
and insulin (F(1,7)¼6.40) in the OGTT, and to the end
point weights of the liver (F(1,7)¼7.54), subcutaneous fat
mass (F(1,7)¼8.29) and deskinned-eviscerated carcasses
(F(1,7)¼6.81) (Table 4).
In females, a different picture emerged. As opposed to
male offspring, female offspring body weight at 2
(F(1,7)¼13.49) and 3 (F(1,7)¼6.86) months of age was
affected by the treatment group, but at 9 months the
gestational body weight gain also became a significant factor
(F(2,6)¼54.63) in a positive direction (Table 3). With respect
to the metabolic parameters (Table 5), the gestational body
weight gain of mothers contributed positively to CHO
oxidation (F(1,7)¼16.059) and inversely to Fat oxidation
(F(1,7)¼21.75). There was a trend for gestational body
weight gain to affect DEE (F(1,7)¼5.65) in a positive
direction. Gestational body weight gain (but not pre-
gestational body weight as was found in males) contributed
to the weight of subcutaneous fat mass (F(1,6)¼17.58) and
the deskinned-eviscerated carcass (F(1,6)¼12.05) in a posi-
tive direction. In none of the cases did litter weight
contribute significantly. The pre-gestational body weight of
mothers significantly affected plasma leptin levels only at 2
months of age (F(1,7)¼8.58) and plasma glucose at 9
months of age (F(1,6)¼38.41).
Discussion
The general aim of these experiments was to investigate the
effects of gestational weight gain in rats on several
parameters related to energy balance and fuel homeostasis
in the offspring. For this purpose, we first assessed whether
pregnant rats were able to increase ingestive behaviour and
body weight, and still were able to produce viable offspring
on inhibition of brain melanocortin (MC) signalling by
chronic i3vt infusion of the MC3/MC4 receptor antagonist
SHU9119 during pregnancy and (part of) lactation. This
situation is very relevant for humans as reduced activation of
brain MC receptors, leading to gestational weight gain, can
be the result of not only genetic30 but also probably
hormonal31 and dietary32 causes. As expected, we observed
increases in food and water intake in pregnant and
particularly lactating rats, and these are regarded as appro-
priate responses necessary to meet the energetic require-
ments of developing offspring. Both food and water intake
were markedly enhanced during pregnancy by i3vt SHU9119
treatment and therefore caused a strong increase in body
weight during pregnancy in these animals. Although Grattan
et al.33 previously reported leptin resistance during the
second phase of pregnancy, this effect is probably not due
to downregulation of MC4 receptors or their downstream
signalling components.
A different picture emerged during lactation, where i3vt
SHU9119 treatment was not effective in increasing food and
water intake above the augmented levels found in vehicle-
treated controls. The most direct explanation for this
inability is that the levels of food and water intake had
reached a certain physiological barrier. Artificially increasing
the litter size34 or concurrent pregnancy35 does not further
augment lactation-induced hyperphagia beyond a certain
level either.35 Johnson et al.36 argued that this physiological
barrier may be related to maximal heat dissipation of
mothers to avoid hyperthermia, as increasing heat dissipa-
tion by cold exposure or removal of fur from the back of
the lactating mother was able to further increase food
intake beyond the pre-existing barrier. It seems likely that,
under these ‘maximized’ intake conditions, MC4 receptor
signalling is already completely abolished , leaving nothing
left to block with SHU9119. In line with this observation
is the report by Crowley et al.37,38 that mRNA expression
of AgRP in the ARC is strongly upregulated, which is
probably mediated by suckling. AgRP may lead to maximal
suppression of brain MC receptor signalling, rendering
additional pharmacological inhibition of brain MC receptors
ineffective.
Another relevant comparison can be made between
pregnant and non-pregnant groups, both i3vt treated with
SHU9119. The observation that the maximized responses in
food and water intake during i3vt SHU9119 treatment were
similar in pregnant and non-pregnant rats suggests a lack of
additional orexigenic neuronal systems during pregnancy
acting independent fromFor parallel toFthe orexigenic
drives mediated by inhibited brain MC activity. With respect
to body weight gain, a different picture emerged. Despite the
similarities in ingestive behaviour in i3vt SHU9119-treated
pregnant and non-pregnant females, body weight gain in
pregnant females was much stronger than in non-pregnant
females treated with SHU9119. This implies that inhibition
of MC signalling in pregnant rats leads to a higher level of
food efficiency relative to that observed in non-pregnant
rats, which does suggest an unknown mechanism acting
independently of MC receptor signalling. A similar compar-
ison between SHU9119-treated lactating and non-lactating
animals is more difficult, as we cannot exclude the
possibility that the higher body weight of SHU9119-treated
non-lactating rats relative to SHU9119-treated lactating rats
may have caused a relatively lower orexigenic drive in the
first group, for example through increased negative feedback
inhibition by leptin. This could be relevant as plasma leptin
levels are normally suppressed during lactation in rats.39–42
Together with an increased expression of some of the short
forms of the leptin receptor (Ob-Re and Ob-Rf) in the
hypothalamus43 and an increased leptin-binding activity in
plasma,41 this could have accounted for the suppression of
MC signalling during lactation as well. An additional
explanation may be that AgRP (as opposed to the ‘passive’
receptor blocker SHU9119) acts as an inverse agonist on MC4
receptors,44 which could gate other orexigenic systems post-
synaptically to maximize ingestive behaviour. These could
include, for example, NPY in projections arising not only
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from ARC neurones but also from the dorsomedial hypotha-
lamus to other food intake-regulating areas.45 A role for
reduced MC signalling has been proposed for the latter, as
novel expression of NPY in DMH has been observed not only
in MC4R null mice46 but also in other rodent models of
hyperphagia such as the diet-induced obese (DIO) mouse.47
At birth, the litter weight of SHU9119-treated mothers was
reduced compared with saline-treated mothers, an effect
owing to a lower litter size, but not to reduced individual
pup weight. We do not know the mechanism underlying this
effect. Although the success rates of pregnancies of
SHU9119-treated (67%) and saline-treated (63%) rats were
about equal, it may be possible that some embryos were
absorbed during the pregnancies of SHU9119-treated
mothers, or that they were cannibalized right after birth
and before counting. Although a direct effect of SHU9119 on
fetal development by placental passage cannot be excluded
entirely, this possibility is highly unlikely because the
molecular properties of cyclic a-MSH analogues prevents
the easy passage of these compounds across the blood–brain
barrier to the peripheral circulation in the infused mothers.48
Over the course of lactation, SHU9119-treated mothers were
able to rear their pups equally well as saline-treated mothers,
indicating that reduced MC signalling does not negatively
affect mother–pup interactions. In fact, body weight in-
creased transiently in pups of SHU9119-treated mothers at
day 16 relative to controls. These effects contrast highly with
those found with central infusion of NPY during pregnancy
and lactation, which causes a very strong suppression of pup
growth.49 Although NPY may function to adapt maternal
metabolism to the energy demands of nursing offspring,37
an overpowering increase of NPY may result in an abrupt
ending of lactation.49 The physiological function of this may
be to protect a mother from starvation if there is not enough
food for both herself and her offspring during periods of
famine. Apparently, low MC activity during pregnancy and
lactation acts in a different way, not diverting fuels away
from fetal development. Following weaning, body weight
gain became more pronounced in male offspring of
SHU9119-treated mothers relative to male offspring from
saline-treated mothers with a final increase of 7.1% at 9
months of age. In females, only a treatment effect was found,
and at 9 months of age the differences were lost. Viewing the
relative weights of organs and tissues of male offspring in
different treatment groups indicated that all (except for the
weight of the full gastrointestinal tract) contributed to this
weight gain but that the relative contributions of retro-
peritoneal (þ36%) and epidydimal (þ20%) fat pads were
found to be the strongest. Increases in visceral fat stores are
often associated with other hallmarks of the metabolic
syndrome, such as insulin resistance and glucose intoler-
ance,50 but we detected no differences in glucose and insulin
responses between offspring of SHU9119-treated and saline-
treated mothers during OGTT and IVGTT.
Although body weight was clearly different in male
offspring of mothers in the two treatment groups, the
general linear model in which litters were nested in
treatments did not attain significant differences between
these or any other tissue or organ weights of the different
treatment groups. It might be that a part of this is explained
by the relatively small number of pregnancies observed in
vehicle and SHU9119-treated groups. On the other hand, the
effect of ‘litter’ in the general linear model was significant in
most cases, indicating that differences between litters within
treatment groups were relatively large compared to differ-
ences between litters in different treatment groups. To
investigate the role of ‘litter,’ we averaged various tissue
and organ weights per litter as dependent factors, and
performed a backward regression analysis in which we
included gestational body weight gain, treatment group as
well as pre-gestational body weight as independent factors.
The latter effect can be imagined if body weight and its
proportions are regulated traits that can be passed on
through genes from one generation to the next.51,52
Consistent with a relatively large contribution of differences
in retroperitoneal fat pads to the observed differences in
body weight between offspring from different treatment
groups was the finding that the gestational weight gain of
mothers was the strongest contributor to the weights of
visceral fat pads in male offspring. To our surprise, however,
we observed that the pre-gestational body weight of mothers
was the strongest contributor to weights of subcutaneous fat,
carcass and various structural organs, including the liver and
the total body weight of male offspring at 9 months of age.
In female offspring, only gestational weight gainFand not
the pre-gestational body weightFcontributed significantly
to weights of tissues and organs at 9 months of age.
Although these effects are very significant in females as well,
they are less conspicuous than in males as body weights of
female offspring from SHU9119-treated and saline-treated
mothers were not significantly different.
There is a large literature on the mechanisms that regulate
energy balance. By definition, these include factors involved
in the control of ingestive behaviour and energy expendi-
ture. An example is the brain MC system, which, upon
reduction of MC4 stimulation, will lead to an increase in
food intake and to a reduction in energy expenditure as seen
in this study. Besides increased food intake, a reduction in
energy expenditure might have played a role in augmenting
body weight gain in i3vt SHU9119-treated mothers as well.
We observed that male offspring of SHU9119-treated rats had
an increased resting metabolic rate (RMR) and daily energy
expenditure (DEE) compared with control males. As differ-
ences were entirely lost when RMR and DEE were calculated
per gram body weight, this indicates that these factors are
within the normal physiological range. Apparently, the trait
of high food efficiency induced by low MC signalling as seen
in the mothers is not passed on to the offspring. In fact,
using backward regression analysis, we found that the pre-
gestational body weight, but not the gestational body weight
gain, was a stronger contributor to DEE, which could
correspond to the contribution of pre-gestational body
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weight to increased weights of metabolically active tissues in
male offspring. Gestational weight gain, on the other hand,
contributed greatly to carbohydrate oxidation, and this
effect was even more pronounced in female offspring. In
the latter event, a significant inverse contribution of
gestational weight gain was found on fat oxidation in female
offspring as well, indicating a shift from fat oxidation to
carbohydrate oxidation. Although the underlying mecha-
nisms have yet to be discovered, these influences of
gestational body weight gain on fuel oxidation could have
dramatic consequences for the offspring when they are
challenged with a high fat diet. At the time of indirect
calorimetry, we also assessed individual food intake and
water intake in the isolated offspring. Although we antici-
pated an increased intake in the offspring from SHU9119-
treated mothers to match the increase in RMR and DEE, we
did not detect any difference. As animals were normally
housed 2–3 per cage, it might be possible that the temporary
individual housing conditions masked the effects of mater-
nal SHU9119 treatment to increase ingestive behaviour.
In summary, the blockade of brain melanocortin receptors
during pregnancy and lactation is able to cause gestational
weight gain, which programmes increased body weight gain
in male offspring rats and, to a lesser extent, in female
offspring rats. The degree of gestational weight gain may
selectively programme increased visceral adipose tissue
storage in male offspring, and these effects could be linked
to increased CHO oxidation relative to oxidation of fats. On
the other hand, maternal factors already present before
pregnancy may contribute to a structural increase of body
weight in male offspring. Apparently, obesogenic factors
such as feeding a high-energy diet, chronic psychological
stress and/or genetic background are much stronger risk
factors for fetal programming of metabolic derangements
than gestational weight gain per se.
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